[Comment] Pooled testing for TB: revisiting a cost-saving innovation

Despite recent advances in screening and diagnosis, tuberculosis remains the deadliest infectious disease. An estimated 10·8 million people developed tuberculosis and 1·25 million died from it in 2023.1 Lagging investment in tuberculosis services and research is a major barrier to elimination. In 2023, of the US$22 billion annual funding target for tuberculosis care, only 26% of funding was available.1 Chronic underinvestment has led to limited and inequitable access to molecular WHO-recommended rapid diagnostics (mWRDs).